Replies to post #226196 on Biotech Values

[DewDiligence]

IGMS—a 2019 IPO—is an ASH loser:

https://www.evaluate.com/vantage/articles/events/conferences/ash-2020-igm-set-become-first-big-casualty

[DewDiligence]

IGMS acquired by Tang Capital for $1.247/sh +CVR—an 11% premium to yesterday’s close—but a 92% discount to IGMS’ 2019 IPO price:

https://www.globenewswire.com/news-release/2025/07/01/3108348/0/en/IGM-Biosciences-Enters-into-Agreement-to-Be-Acquired-by-Concentra-Biosciences-for-1-247-in-Cash-per-Share-Plus-a-Contingent-Value-Right.html